Compare · EOG vs PRTG
EOG vs PRTG
Side-by-side comparison of EOG Resources Inc. (EOG) and Portage Biotech Inc. (PRTG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EOG and PRTG operate in Oil & Gas Production (Energy), so they compete in similar markets.
- EOG is the larger of the two at $77.02B, about 627.4x PRTG ($122.8M).
- EOG has hit the wire 13 times in the past 4 weeks while PRTG has been quiet.
- EOG has more recent analyst coverage (25 ratings vs 5 for PRTG).
EOG Resources Inc.
EOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil, and natural gas and natural gas liquids. Its principal producing areas are in New Mexico and Texas in the United States; the Republic of Trinidad and Tobago; the People's Republic of China; and the Sultanate of Oman. As of December 31, 2020, it had total estimated net proved reserves of 3,220 million barrels of oil equivalent, including 1,514 million barrels (MMBbl) of crude oil and condensate reserves; 813 MMBbl of natural gas liquid reserves; and 5,360 billion cubic feet of natural gas reserves. The company was formerly known as Enron Oil & Gas Company. EOG Resources, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.
Portage Biotech Inc.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Latest EOG
- Chairman & CEO Yacob Ezra Y sold $5,466,670 worth of shares (35,942 units at $152.10), decreasing direct ownership by 13% to 242,451 units (SEC Form 4)
- Director Clark Janet F was granted 314 shares, increasing direct ownership by 0.64% to 49,555 units (SEC Form 4)
- Director Crisp Charles R was granted 283 shares, increasing direct ownership by 0.45% to 63,443 units (SEC Form 4)
- Director Daniels Robert P was granted 446 shares, increasing direct ownership by 1% to 35,199 units (SEC Form 4)
- EVP & Chief Legal Officer Donaldson Michael P was granted 148 shares, increasing direct ownership by 0.14% to 107,894 units (SEC Form 4)
- Director Dugle Lynn A was granted 42 shares, increasing direct ownership by 0.55% to 7,696 units (SEC Form 4)
- Director Gaut C Christopher was granted 143 shares, increasing direct ownership by 0.62% to 23,063 units (SEC Form 4)
- Director Kerr Michael T. was granted 365 shares, increasing direct ownership by 2% to 23,296 units (SEC Form 4)
- EVP & COO Leitzell Jeffrey R. was granted 4 shares, increasing direct ownership by 0.00% to 88,054 units (SEC Form 4)
- Chairman & CEO Yacob Ezra Y was granted 2 shares, increasing direct ownership by 0.00% to 278,393 units (SEC Form 4)
Latest PRTG
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 6-K filed by Portage Biotech Inc.
- SEC Form 424B5 filed by Portage Biotech Inc.
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 6-K filed by Portage Biotech Inc.
- AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
- SEC Form S-8 filed by Portage Biotech Inc.
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 424B3 filed by Portage Biotech Inc.
- SEC Form 6-K filed by Portage Biotech Inc.